The various nonspecific CDK9 inhibitors that have been tested in preclinical and clinical settings produce a range of toxicities and side effects that affect the stomach and liver and can also trigger hypokalemia and neutropenia (7, 25). This evidence concerns the gene CDK9 and Hypokalemia.